AVIR Share Price | Atea Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does Atea Pharmaceuticals, Inc. do?

Overview:Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics in the Pharmaceuticals & Biotechnology industry.Financial Snapshot:Most recent Net Profit: -34 Million (Quarterly Results - Mar 2025) Market cap: USD 274.71 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.03 Return on Equity: -33.93% Price to Book: 0.67Contact Details:Address: 125 SUMMER STREET, 16TH FLOOR, BOSTON MA : 02110 Tel: 1 857 2048109 Fax: 1 302 6555049 Website: https://ateapharma.com/

Q: Is Atea Pharmaceuticals, Inc. overvalued or undervalued?

As of 28 February 2023, Atea Pharmaceuticals, Inc. has moved from a fair valuation to a status of does not qualify, indicating significant concerns regarding its financial health and market position. The company is currently deemed overvalued, particularly given its negative P/E ratio due to losses, a Price to Book Value of 0.66, and an EV to EBITDA of 0.94. These metrics suggest that the company's valuation does not align with its financial performance.In comparison to its peers, Atea Pharmaceuticals' valuation appears unfavorable. For instance, Soleno Therapeutics, Inc. has a significantly lower EV to EBITDA ratio of -18.16, while Phibro Animal Health Corp. stands out as very attractive with a P/E ratio of 21.68. Additionally, Atea's ROE stands at -33.93%, which further underscores its struggles relative to the industry. The recent stock performance shows a 1-month return of 14.48%, outperforming the S&P 500's 3.83%, but this does not mitigate the overall valuation concerns.

Q: Is Atea Pharmaceuticals, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Atea Pharmaceuticals, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. However, both the weekly and monthly Bollinger Bands indicate a bearish trend. The daily moving averages show a mildly bullish signal, but the KST and OBV metrics are both mildly bearish on the weekly and monthly timeframes. In terms of performance, Atea Pharmaceuticals has underperformed significantly compared to the S&P 500 across multiple periods, with a 1-year return of -25.56% versus the S&P's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

338.44 k

Shareholding (Dec 2025)

FII

2.87%

Held by 48 FIIs

DII

62.27%

Held by 38 DIIs

Promoter

3.18%

How big is Atea Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Atea Pharmaceuticals, Inc. has a market capitalization of 274.71 million and reported net sales of 0.00 million with a net profit of -139.48 million over the latest four quarters. The balance sheet as of Dec'24 shows shareholder's funds of 438.87 million and total assets of 464.67 million.

View full answer

What does Atea Pharmaceuticals, Inc. do?

22-Jun-2025

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics. As of March 2025, it has a market cap of $274.71 million and reported a net profit loss of $34 million.

View full answer

Who are in the management team of Atea Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Atea Pharmaceuticals, Inc. is led by Mr. Jean-Pierre Sommadossi, who is the Chairman of the Board, Chief Executive Officer, and Founder.

View full answer

Is Atea Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of February 28, 2023, Atea Pharmaceuticals, Inc. is considered overvalued with significant financial concerns, reflected in its negative P/E ratio, low Price to Book Value, and unfavorable comparison to peers, despite a recent stock performance that outpaced the S&P 500.

View full answer

Is Atea Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Atea Pharmaceuticals' technical trend is neutral with mixed indicators, showing a shift from mildly bullish to sideways, while significantly underperforming the S&P 500 with a 1-year return of -25.56%.

View full answer

Compare Atea Pharmaceuticals, Inc. with Similar Stocks

Ovid Therapeutics, Inc.Fulcrum Therapeutics, Inc.Third Harmonic Bio, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 482 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.04

Return on Equity

-46.56%

Price to Book

1.53

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-45 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

47.24%

6 Months

83.79%

1 Year

66.56%

2 Years

31.28%

3 Years

77.67%

4 Years

-26.79%

5 Years

-92.14%

Atea Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-220.39%

EBIT to Interest (avg)

-79.08

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.29

Tax Ratio

0.65%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

80.98%

ROCE (avg)

ROE (avg)

2.23%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.53

EV to EBIT

-0.93

EV to EBITDA

-0.93

EV to Capital Employed

-12.09

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-46.56%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 34 Schemes (31.68%)

Foreign Institutions

Held by 48 Foreign Institutions (2.87%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -34.03% vs 14.54% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-54.80",
          "val2": "-38.90",
          "chgp": "-40.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.90",
          "val2": "-33.50",
          "chgp": "-34.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.00% vs -23.82% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-180.50",
          "val2": "-192.50",
          "chgp": "6.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-158.30",
          "val2": "-168.40",
          "chgp": "6.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-54.80

-38.90

-40.87%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-44.90

-33.50

-34.03%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -34.03% vs 14.54% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-180.50

-192.50

6.23%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-158.30

-168.40

6.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 6.00% vs -23.82% in Dec 2024

All Annual Results

Company CV

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of orally available selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its lead product candidate, AT-527, is an orally administered, antiviral agent for the treatment of patients infected with SARS-CoV-2. It provides AT-787 for the treatment of hepatitis C. It offers AT-752 for the treatment of dengue, which is an oral, purine nucleotide prodrug for the treatment of dengue virus, a mosquito-borne viral infection. The Company is evaluating two lead compounds, AT-889 and AT-934, nucleoside pyrimidine prodrugs and other compounds for the treatment of respiratory syncytial virus (RSV).

Company Coordinates

Company Details

125 SUMMER STREET, 16TH FLOOR , BOSTON MA : 02110

Tel: 1 857 2048109

https://ateapharma.com/

Registrar Details